Gilead Sciences												
Date of publication: 30.06.2025												
	Full Name	HCPs: City of Principal Practice / HCOs: City where registered	Country of Principal Practice	Principal Practice Address	Unique country identifier OPTIONAL		Contribution to costs of Events (Art. 3.01.1.b & 3.01.2.a)			Fee for service and consultancy (Art. 3.01.1.c & 3.01.2.c)		
	(Art. 1.01)	(Art. 3)	(Schedule 1)	(Art. 3)	(Art. 3)	Donations and Grants to HCOs / (Art. 3.01.1.a)	Sponsorship agreements with HCOs / third parties appointed by HCOs to manage an Event	Registration Fees	Travel & Accommodation	Fees	Related expenses agreed in the fee for service or consultancy contract, including travel & accommodation relevant to the contract	
HCPs	INDIVIDUAL NAMED DISCLOSURE - one line per HCP (i.e. all transfers of value during a year for an individual HCP will be summed up. Itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
	Hallgerður Lind Kristjánsdóttir	Reykjavik		Reykjafold 4				-	97.445	-	-	97.445
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02 % of the number of Recipients included in the aggregate disclosure in the total number											
	of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02							0%	0%	0%	0%	0%
нсоѕ	INDIVIDUAL NAMED DISCLOSURE - one line per HCO (i.e. all transfers of value during a year for an individual HCO will be summed up: itemization should be available for the individual Recipient or public authorities' consultation only, as appropriate.											
	Landspitali University Hospital	Reykjavik	Iceland	Reykjafold 4	I	-	-	-	-	337.805	-	337.805
	OTHER, NOT INCLUDED ABOVE- (where information cannot be disclosed on an individual basis for legal reasons											
	Aggregate amount attributable to transfers of value to such Recipients - Art 3.02											
	Number of Recipients in aggregate disclosure - Art 3.02											
	% of the number of Recipients included in the aggregate disclosure in the total number of Recipients disclosed - Art 3.02					0%	0%	0%	0%	0%	0%	0%
	AGGREGATE DISCLOSURE											
R&D	Transfers of Value re Research & Development as defined in Article 3.04 and Schedule 1											